Trials / Unknown
UnknownNCT02556762
Simultaneous Modulated Accelerated Boost Versus Standard Dose Radiotherapy in Esophageal Cancer
Phase III Randomized Controlled Trial of Definite Chemoradiotherapy in Patients With Esophageal Cancer: Simultaneous Modulated Accelerated Boost Versus Standard Dose Radiotherapy
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 202 (estimated)
- Sponsor
- Chuangzhen Chen · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This randomized phase III trial is to compare simultaneous modulated accelerated boost with standard dose radiotherapy given together with chemotherapy in treating patients with esophageal squamous cell carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Radiotherapy with simultaneous modulated accelerated boost | Radiotherapy: 66Gy/30F to the gross tumor and 50Gy/25 to subclinical diseases |
| RADIATION | Standard dose radiotherapy | Radiotherapy: 50Gy/25F to both gross tumor and subclinical disease |
| DRUG | PF | Chemotherapy: Cisplatin and 5fluorouracil |
Timeline
- Start date
- 2015-08-01
- Primary completion
- 2022-03-01
- Completion
- 2024-12-31
- First posted
- 2015-09-22
- Last updated
- 2024-02-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02556762. Inclusion in this directory is not an endorsement.